Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2009

China Buys $12.8M of Hepatitis A Vaccine from Sinovac

China Buys $12.8M  of Hepatitis A Vaccine from Sinovac

Chinese government purchases hepatitis A vaccine from Sinovac

  • The Chinese Ministry of Public Health placed an ¥87 million ($12.8 million) order for Sinovac Biotech's inactivated hepatitis A vaccine, Healive. The vaccine will be used in a campaign targeted at children from 18 months to 12 years in nine provinces across the country, says the company.

    Sinovac is a China-based biopharmaceutical company focused on producing and developing vaccines for use against human infectious disease. In 2008, Sinovac collaborated with the Ministry of Health to provide hepatitis A vaccine to people living in the Sichuan province who were affected by the major earthquake there. Sinovac says that it recently completed expansion on a filing and packaging plant and that its annual capacity is now 20 million doses.

    "We are very pleased to have established a public market for our inactivated hepatitis A vaccine, Healive, through this supply agreement with the MOH, as we are focusing our efforts in 2009 on both the public and private pay markets," says Weidong Yin, chairman, president, and CEO of Sinovac.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »